查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
視網膜健康的全球市場:市場規模 - 各適應症，各治療法，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1170433

視網膜健康的全球市場:市場規模 - 各適應症，各治療法，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)

Retina Health Market Size- By Disease Indication, By Treatment, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 225 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球視網膜健康的市場規模，預計至2032年達到215億9,000萬美元，以7.8％的年複合成長率成長。

為了保持最佳的視網膜健康，提供各種治療方法和藥物，知道選項的人越多，產品的市場預計今後慢慢擴大。

北美市場，由於視網膜疾病高的發生率和該地區的主要企業的發展等要素，預計急速擴的。亞太地區市場，由於醫療基礎設施的迅速擴大和平均每人的所得增加，預計大幅度擴大。

本報告提供全球視網膜健康市場相關調查，市場動態，市場變數與展望，各適應症、治療方法、流通管道、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球視網膜健康市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球視網膜健康市場:各適應症(2019年～2032年(100萬美元))

  • 老年性黃斑部病變(AMD)
  • 糖尿病視網膜病變
  • 遺傳性視網膜疾病
  • 視網膜胚細胞瘤
  • 視網膜靜脈阻塞症
  • 其他

第7章 全球視網膜健康市場:各治療法(2019年～2032年(100萬美元))

  • 藥物
  • 治療
  • 基因治療
  • 營養療法
  • 外科手術
  • 其他

第8章 全球視網膜健康市場:各流通管道(2019年～2032年(100萬美元))

  • 醫院藥局
  • 零售藥局
  • 其他

第9章 全球視網膜健康市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • Allergan PLC
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Applied Genetic Technologies Corporation
  • Gensight Biologics
  • Hemera Biosciences LLC
  • Mejragtx Ltd.
  • Novaritis AG
  • Oxford Biomedica PLC
  • Regenxbio Inc.
  • Santen Pharmaceutical Inc.
  • Spark Therapeutics Inc.
簡介目錄
Product Code: HLCA2219

Global Retina Health Market Overview:

According to SPER Market Research, the Global Retina Health Market is estimated to reach USD 21.59 billion by 2032 with a CAGR of 7.8%.

To create electrical signals from the light that enters the eye, the retina-a tiny layer situated at the back of the eyes-must first convert the light into those signals. Images are created by the brain after it has processed the impulses. A Healthy retina can help avoid blindness as well as several visual problems and impairments. The two most common retinal diseases, macular degeneration and diabetic retinopathy impact millions of people globally. A wide range of treatments and medications are available to guarantee optimal retina Health, and as more people become aware of these options, the market for these products will grow gradually in the years to come.

Impact of COVID-19 on the Global Retina Health Market:

The huge impact of COVID-19 pandemic has had several negative effects on people's Health all across the world. A substantial social and economic burden has been placed on individuals all across the world as a result of the aftermath. While big politicians are putting new frameworks into place and companies are embracing cutting-edge expansion methods to stay relevant, people are dealing with a variety of emotional anguish. The increase in instances has exacerbated emotional and financial problems, particularly for the elderly. The younger population has also been experiencing difficulties as a result of job losses and is choosing family care to deal with the effects. The development of a vaccine for COVID-19 is the main area of concentration, which diverts attention from other diseases.

Scope of the Report:

Report Metric Details:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Disease Indication, By Treatment, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Allergan PLC, Applied Genetic Technologies Corporation, Gensight Biologics, Hemera Biosciences LLC, Meiragtx Ltd., Novartis AG, Oxford Biomedica PLC, Regenxbio Inc., Santen Pharmaceuticals Inc., Spark Therapeutics Inc.

Global Retina Health Market Segmentation:

  • By Disease Indication: Based on the Disease Indication, Global Retina Health Market is segmented as; Age-Related Macular Degeneration, Diabetic Retinopathy, Diabetic Retinopathy, Inherited Retinal Diseases, Retinoblastoma, Retinal Vein Occlusion, Others.
  • By Treatment: Based on the Treatment, Global Retina Health Market is segmented as; Drugs, Therapy, Gene Therapy, Nutrition Therapy, Surgery, others.
  • By Distribution Channel: Based on the Distribution Channel, Global Retina Health Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Others.
  • By Region: The North American retina Health market is anticipated to expand quickly due to a variety of driving factors, including the high incidence of retinal diseases and the development of key market companies in the region. Due to the rapidly expanding Healthcare infrastructure and growing per capita income, the Asia-Pacific retina Health market will also experience significant expansion. A substantial senior population and increased public awareness of eye Health will also contribute to the market expanding at a strong rate.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Retina Health Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Retina Health Market, By Disease Indication, 2019-2032 (USD Million)

  • 6.1. Age-Related Macular Degeneration
  • 6.2. Diabetic Retinopathy
  • 6.3. Diabetic Retinopathy
  • 6.4. Inherited Retinal Diseases
  • 6.5. Retinoblastoma
  • 6.6. Retinal Vein Occlusion
  • 6.7. Others

7. Global Retina Health Market, By Treatment, 2019-2032 (USD Million)

  • 7.1. Drugs
  • 7.2. Therapy
  • 7.3. Gene Therapy
  • 7.4. Nutrition Therapy
  • 7.5. Surgery
  • 7.6. others

8. Global Retina Health Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Hospital Pharmacy
  • 8.2. Retail Pharmacy
  • 8.3. Others

9. Global Retina Health Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Allergan PLC
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Applied Genetic Technologies Corporation
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 Gensight Biologics
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 Hemera Biosciences LLC
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Mejragtx Ltd.
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 Novaritis AG
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Oxford Biomedica PLC
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 Regenxbio Inc.
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Santen Pharmaceutical Inc.
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Spark Therapeutics Inc.
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments